A 54-Week Randomized Trial Comparing Home Monitoring to Usual Care in Adults with Rheumatic Disease-Related Interstitial Lung Disease

What this Trial Is About

Researchers are studying a home monitoring approach to improve care for adults with interstitial lung disease related to systemic rheumatic diseases. This 54-week, multi-center randomized controlled trial compares home monitoring using bi-weekly lung function and patient-reported outcome measurements against the usual care of fixed-interval hospital visits. The trial aims to see if home monitoring can detect disease progression earlier than standard hospital visits. Participants are assigned to one of two groups one group receives usual care with scheduled hospital visits every six months, while the other group uses a home monitoring strategy that involves remote collection of lung function data, patient-reported outcomes, blood oxygen levels during a sit-to-stand test, and temperature measurements twice weekly. The home monitoring system includes an algorithm to evaluate risks of deterioration or infection, allowing for event-driven management. Throughout the study, participants complete questionnaires and perform lung function tests at home or during hospital visits. Researchers will assess outcomes such as early detection of disease progression, changes in lung function, respiratory symptoms, and events related to pulmonary fibrosis. The study includes safety monitoring and requires participants to have internet access and be able to use electronic devices. The total participation duration is 54 weeks.

Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases